To strengthen its oncology pipeline, Daiichi Sankyo acquires the biotech company U3 Pharma in Martinsried, Germany.
In addition, Daiichi Sankyo lays the foundation for further growth in Europe by acquiring the marketing rights for the osteoporosis drug Evista® (with the active ingredient raloxifene) from Eli Lilly and Company, and by establishing new affiliates in Istanbul and Dublin.
Moreover, the number of field force employees is significantly increased by taking on highly qualified people from Merck Serono in various European countries.